Clinical Trials Logo

Filter by:
NCT ID: NCT03336333 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

SEQUOIA
Start date: October 31, 2017
Phase: Phase 3
Study type: Interventional

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.

NCT ID: NCT03335670 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

Start date: November 3, 2017
Phase: Early Phase 1
Study type: Interventional

This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor patients and if that distribution is consistent through repeated scans. This is an RDRC study - as such, the images obtained for this study cannot be used clinically or shared with treating oncologists.

NCT ID: NCT03335605 Active, not recruiting - Clinical trials for CVI - Common Variable Immunodeficiency

Improving the Diagnosis of Common Variable Immune Deficiency

Start date: May 1, 2019
Phase:
Study type: Observational

This is an observational, case-control study with a single blood draw among two cohorts, patients with antibody deficiency (e.g., CVID) and healthy controls. Samples will be analyzed by mass cytometry (CyTOF) to examine the major signaling pathways of all circulating innate and adaptive immune cell types, as well as whole exome sequencing. The goal is to improve our general understanding of the human immune response to infections and the diagnosis of CVID.

NCT ID: NCT03334942 Active, not recruiting - Clinical trials for Posttraumatic Stress Disorder

Addressing Traumatic Stress Symptoms in Children

Start date: November 2, 2017
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the effectiveness of the Child and Family Traumatic Stress Intervention (CFTSI), provided soon after a violent traumatic event, in producing significant and sustained reduction in PTSS among assault injured youth.

NCT ID: NCT03334617 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

HUDSON
Start date: December 18, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

NCT ID: NCT03334500 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

Start date: July 14, 2017
Phase: Early Phase 1
Study type: Interventional

Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer [18F]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic disease. Imaging will be compared with pathology results, including additional research assays when possible.

NCT ID: NCT03334305 Active, not recruiting - Malignant Glioma Clinical Trials

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

ACTION
Start date: May 16, 2018
Phase: Phase 1
Study type: Interventional

It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor. In this research study, we will use a patient's tumor to make a vaccine which we hope will stimulate T-cells to kill tumor cells and leave normal cells alone. High grade gliomas (HGGs) are very aggressive and difficult for the body's immune system to attack. Before T-cells can become active against tumor cells, they require strong stimulation by special "stimulator" cells in the body called Dendritic Cells (DCs) which are also part of the immune system. DCs can recognize the cancer cells and then activate the T lymphocytes, and create this strong stimulation. The purpose of this research study is to learn whether anti-tumor T-cells and anti-tumor DC vaccines can be given safely. Most importantly, this study is also to determine whether the T-cells and DC vaccines can stimulate a person's immune system to fight off the tumor cells in the brain.

NCT ID: NCT03333629 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes

Start date: November 29, 2017
Phase: Phase 4
Study type: Interventional

Autism spectrum disorder (ASD) is defined by impaired social engagement and social communication, and repetitive, restricted, or stereotyped behaviors and interests. The average age of diagnosis in the US is after the fourth birthday. However, children who start ASD-specific early intervention have better outcomes than children start later. The current study will address a gap identified by the US Prevention Services Task Force, namely that children detected through screening respond positively to early intervention. This study will directly relate early detection strategies to early intervention, and measure the impact of age of intervention onset on outcomes when children are entering kindergarten. Local pediatric providers will be randomized to provide either usual care, or to an experimental condition in which autism early detection strategies are enhanced through the addition of specific procedures. Across all sites, 8,000 children will be recruited through their participating pediatric practice. Qualifying children will receive up to one year of early intensive behavioral intervention, after getting an ASD diagnosis. Primary outcome measures will include children's cognitive functioning and ASD symptom severity, which will be measured at multiple time points. The investigators predict that this study will inform early detection strategies which will result in improving children's social and cognitive functioning, mitigating lifespan disability, reducing societal costs, and improving personal well-being and productivity of individuals with ASD.

NCT ID: NCT03333616 Active, not recruiting - Clinical trials for Adrenocortical Carcinoma

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Start date: December 28, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendocrine differentiation. Given preliminary results, the study is being tested in additional patients with bladder or upper tract carcinoma with variant histology at this time while the adrenocortical carcinoma, other rare genitourinary malignancies arms have closed to accrual -The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab

NCT ID: NCT03333590 Active, not recruiting - Clinical trials for Duchenne Muscular Dystrophy

Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy

Start date: November 6, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The proposed clinical trial study of rAAVrh74.MCK.GALGT2 for duchenne muscular dystrophy (DMD) patients. There will be a modified intravascular limb infusion (ILI) procedure that will be used to sequentially deliver vector to each whole lower limb of DMD subjects via a major lower limb artery.